

NEWSLETTER

ISSUE 5 - December 2018

WELCOME TO THE 5th Edition of the EHVA NEWSLETTER

Welcome to the fifth edition of the **European HIV Vaccine Alliance (EHVA)** newsletter. EHVA is an alliance of 39 partners in Europe, Sub-Saharan Africa and North America. We work collaboratively to contribute to the development of safe and effective vaccines aimed at stopping HIV infections and AIDS. Through a multidisciplinary platform, EHVA facilitates the development and evaluation of novel prophylactic and therapeutic HIV vaccines, with the aim to select at least two of the most promising vaccine candidates for clinical development. We work closely with research partners across several Sub-Saharan African countries, and with the European and Developing Countries Clinical Trials Partnership (EDCTP) to ensure that the vaccine candidates are relevant for and can be evaluated in countries where vaccines are most needed. The work of EHVA is funded through a 5-year grant from the European Union's Horizon 2020 programme and the Swiss Government.

If you want to learn more about EHVA please visit our website.

EHVA Website

EHVA's NEWS & UPDATES



EHVA's FIRST CLINICAL TRIAL INITIATED

The European HIV Vaccine Alliance announced the start of the EHVA T01/ANRS VRI05 trial which is planned to take place in six European countries. EHVA-T01 / ANRS VRI05, a phase I/II placebo-controlled randomised trial, will evaluate an experimental therapeutic HIV vaccine and an experimental immunotherapy drug in people living with HIV. To learn more about the trial please go to <http://www.ehv-a.eu/news>

COMMUNITY CONSULTATION MEETING



Brussels, 15 November 2018

The European AIDS Treatment Group (EATG) organised a one-day Community Consultation meeting around the EHVA trial in Brussels, on Thursday 15 November 2018. 19 participants consisting of members of the EATG and their network of people living with HIV as well as project consortium members attended the meeting. EATG is in the process of establishing a network of community contacts in the six cities where the study takes place, who can support those who are interested in participating to the study by addressing any questions they may have - thus adopting a peer-to-peer approach. This approach is important when it comes to the trial participants' expectations & knowledge about HIV cure research. Those and other psychosocial aspects related to participation to the trial will be investigated by a survey that was presented during the consultation and received input from the participants.

The aim of the meeting was to inform this network of community contacts about the study and their eventual role in the project. The participants also had a possibility to comment on the different aspects of the study and the community involvement so far.

For a more detailed report about the meeting please go to [EATG Website](#)

GLOBAL HIV/AIDS NEWS



WORLD AIDS DAY "Know Your Status"

As each year this 1st December the world showed solidarity with the millions of people living with HIV and commemorated those who have died from AIDS and related illnesses. Founded 30 years ago, in 1988, World AIDS day was the first ever global health day. Significant progress has been made in the fight against HIV/AIDS since. Today about **3 in 4 people living with HIV know their status**. We need to reach all people living HIV who are still unaware of their status and we need to ensure they are provided with quality treatment and care. Knowing their status will empower people to make the right choices regarding treatment and prevention and to protect

themselves and their loved ones. For further reading on this year's World AIDS Day, go to [World AIDS Day](#) and on the importance of knowing one's status to [Knowlegde is Power](#)

EHVA stands in solidarity with all people affected by HIV and AIDS and strengthens its resolve to help develop safe and effective therapeutic and preventative vaccines.

For our latests news go to <http://www.ehv-a.eu/news>

DID YOU KNOW?

Latest global HIV Facts & Figures



UNAIDS Data - Global HIV Statistics

- **36.9 million** (31.1 million – 43.9 million) people globally were living with HIV.
- **21.7 million** (19.1 million–22.6 million) people were accessing antiretroviral therapy.
- **1.8 million** (1.4 million–2.4 million) people became newly infected with HIV.
- **940 000** (670 000–1.3 million) people died from AIDS-related illnesses.
- **77.3 million** (59.9 million–100 million) people have become infected with HIV since the start of the epidemic.
- **35.4 million** (25.0 million–49.9 million) people have died from AIDS-related illnesses since the start of the epidemic.

For more information go to [UNAIDS facts sheet](#)

2018 HIV EVENTS – REPORTS

HIVR4P 2018



Thousands of researchers gathered in Madrid, Spain, this October for the biennial HIV Research for Prevention (HIVR4P) conference. With two vaccine candidates in ongoing efficacy trials, numerous other candidates entering clinical testing, and a flurry of activity in developing antibodies for prophylaxis, the field seems undeniably enthusiastic about the prospects for developing new HIV prevention strategies. For more information check the rapporteur highlights at [HIVR4P](#) and the [IAVI report](#)



The 2018 edition of the HIV Therapy Congress convened in Glasgow more than 2,200 delegates from all over the world. From Sunday 28 to Wednesday 31 October 2018, the most recent advancement in the treatment of HIV infection were discussed. Important data were presented related to innovative two-drug regimens of dolutegravir plus lamivudine or dolutegravir and rilpivirine, confirming these could be suitable options for both naive patients and as maintenance strategy. Also, long-acting cabotegravir and rilpivirine seem to have a durable efficacy as two-drug IM maintenance therapy for HIV-1 infection. Important results came also from studies about new drugs for people with very limited treatment options available, such as the attachment inhibitor fostemsavir or the monoclonal antibody imalizumab. All abstracts, posters and webcasts from sessions are available on the conference website www.hivglasgow.org.

Upcoming events



The next IAS conference on HIV Science will take place from
21 – 24 July 2019 in Mexico City, Mexico.

The abstract submission deadline is from 1 Dec 2018 until 22 Jan 2019.

For more information please check: <http://www.ias2019.org/>



The next Conference on Retroviruses and Opportunistic Infections will take place from
4-7 March 2019 in Seattle, Washington

For more information please check: <http://www.croiconference.org/about>

If you have any feedback, questions or suggestions, please contact us! We look forward to hearing from you!

EHVA CONTACT INFORMATION

For all enquiries contact@ehv-a.eu
Management Team: pmo@ehv-a.eu
Media enquiries: communication@ehv-a.eu



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 681032.



This project has received funding from the Swiss government (through the State Secretariat for Education, Research and Innovation, SERI) under grant agreement No. 15.0337. The opinions expressed and arguments employed herein do not necessarily reflect the official views of the Swiss Government.

Copyright © 2015 EHVA

If you have questions about our mailing list or would like to unsubscribe from this newsletter, please contact communication@ehv-a.eu

This email was sent to pmo@ehv-a.eu

[why did I get this?](#) [unsubscribe from this list](#) [update subscription preferences](#)

EHVA · Van Diemenstraat 48 · Amsterdam, NH 1013 · Netherlands

